Sunday, May 20, 2012

Afatinib and EGFR my other Metabolic pathway

Afatinib, planned trade name Tomtovok (previously Tovok), is undergoing a Phase III clinical trials for non-small cell lung carcinoma NSCLC), and was developed by Boehringer Ingelheim. 


Afatinib

















Mechanism of action
Afatinib is a next generation tyrosine kinase inhibitor (TKI) that irreversibly inhibits human epidermal growth factor receptor 2 Her2 (ErbB2) and epidermal growth factor receptor EGFR (ErbB1) tyrosine kinases.




Conclusion

Afatinib monotherapy demonstrated encouraging activity in treatment-refractory NSCLC during clinical trials with squamous histology that merits further evaluation.










Posted by at

1 comment:

  1. AnonymousMay 21, 2012 at 11:26 PM

    It looks as if both of our drugs use HER2 expression as a target. I wonder if utilizing your drug as a conjugate on the anitbody of mine would create a more specific target or if utilizing both in conjunction would have a stronger effect?

    ReplyDelete

Subscribe to: Post Comments (Atom)